[1]刘兰荣,李红,时立新.Alstrm综合征的研究进展[J].国际内分泌代谢杂志,2017,37(05):333-336.
　Liu Lanrong,Li Hong,Shi Lixin..Research progress of Alstrm syndrome[J].International Journal of Endocrinology and Metabolism,2017,37(05):333-336.
点击复制

Alström综合征的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
37
期数:
2017年05期
页码:
333-336
栏目:
综述
出版日期:
2017-09-20

文章信息/Info

Title:
Research progress of Alström syndrome
作者:
刘兰荣; 李红; 时立新
550004 贵阳,贵州医科大学附属医院内分泌代谢科
Author(s):
Liu Lanrong;  Li Hong;  Shi Lixin.
Department of Endocrinology and Metabolism, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
关键词:
Alströ; m综合征;  ALMS1基因;  细胞纤毛病
Keywords:
Alströ; m syndrome;  ALMS1 gene;  Ciliopathies
文献标志码:
A
摘要:
Alström综合征是一种隐性的单基因细胞纤毛遗传性疾病,由ALMS1基因突变引起,其典型特征为视锥-杆体细胞营养不良、听力损失、儿童腹型肥胖、胰岛素抵抗和高胰岛素血症、2型糖尿病、高甘油三酯血症、成年期身材矮小、心肌病和进行性肺、肝、肾功能障碍。ALMS1基因缺陷包括插入、删除和无义突变,导致蛋白质截短。ALMS1蛋白位于所有受疾病影响的纤毛细胞中心体、基底部和细胞溶质组织。具有维护纤毛功能和结构的作用,另外在细胞内运输、纤毛信号通路调节、细胞分化等方面也发挥作用。但ALMS1确切的致病机制不明。Alström综合征不同年龄阶段临床特征不同,初步诊断依赖于临床症状,但确诊依赖于ALMS1基因检测。目前,Alström综合征尚无根治方法,主要治疗措施局限于临床症状的对症处理和生活质量的改善,因此必须继续研究疾病的分子致病机制,进而明确基因治疗靶点,开辟个性化治疗道路。
Abstract:
Alström syndrome, a recessive monogenic ciliopathy caused by mutations in ALMS1 gene, is typically characterized by cone-rod dystrophy, hearing loss, childhood truncal obesity, insulin resistance, hyperinsulinemia, type 2 diabetes, hypertriglyceridemia, short stature in adulthood, cardiomyopathy, progressive pulmonary, hepatic and renal dysfunction. ALMS1 gene defects include insertions, deletions and nonsense mutations leading to protein truncations. ALMS1 protein is found in centrosomes, basal bodies and cytosol of all tissues affected by the disease. In addition to its role in ciliary function and structure maintenance, this protein has been implicated in intracellular trafficking, regulation of cilia signaling pathways, cellular differentiation and among others. The precise function of ALMS1 protein remains elusive. The preliminary diagnosis is made on the basis of different clinical characteristics of different age stages. Genetic testing would confirm the diagnosis. So far, there is no specific therapy for Alström syndrome, the main treatment is limited to improve clinical symptoms and quality of life for patients. Researching molecular pathogenic mechanism and gene therapy targets of the disease, could open the way to personalized therapies for individuals with Alström syndrome in the future.

参考文献/References:

[1] Marshall JD,Beck S,Maffei P,et al. Alström syndrome[J].Eur J Hum Genet,2007,15(12):1193-1202. DOI:10.1038/sj.ejhg.5201933.
[2] Marshall JD, Bronson RT, Collin GB,et al. New Alström syndrome phenotypes based on the evaluation of 182 cases[J].Arch Intern Med,2005,165(6):675-683.DOI:10.1001/archinte.165.6.675.
[3] Marshall JD, Hinman EG, Collin GB,et al. Spectrum of ALMS1 variants and evaluation of genotype-phenotype correlations in Alström syndrome[J].Hum Mutat,2007,28(11):1114-1123.DOI:10.1002/humu.20577.
[4] Aldahmesh MA, Abu-Safieh L, Khan AO,et al. Allelic heterogeneity in inbred populations: the Saudi experience with Alström syndrome as an illustrative example[J].Am J Med Genet A,2009,149A(4):662-665.DOI:10.1002/ajmg.a.32753.
[5] 罗建华,于瑞萍,顾燕,等. Alström综合征临床特征分析及2例报告[J].中华内分泌代谢杂志,2011,27(11):897-900.DOI:10.3760/cma.j.issn.10006699.2011.07.007.
[6] Marshall JD, Maffei P, Collin GB,et al. Alström syndrome: genetics and clinical overview[J].Curr Genomics,2011,12(3):225-235. DOI: 10.2174/138920211795677912.
[7] Marshall JD, Muller J, Collin GB,et al. Alström Syndrome: mutation spectrum of ALMS1[J].Hum Mutat,2015,36(7):660-668. DOI:10.1002/humu.22796.
[8] Ozantürk A, Marshall JD, Collin GB,et al. The phenotypic and molecular genetic spectrum of Alström syndrome in 44 Turkish kindreds and a literature review of Alström syndrome in Turkey[J].J Hum Genet,2015,60(1):1-9. DOI:10.1038/jhg.2014.85.
[9] Jagger D, Collin G, Kelly J, et al. Alström syndrome protein ALMS1 localizes to basal bodies of cochlear hair cells and regulates cilium-dependent planar cell polarity[J].Hum Mol Genet,2011,20(3):466-481. DOI:10.1093/hmg/ddq493.
[10] Collin GB, Marshall JD, King BL,et al. The Alström syndrome protein, ALMS1, interacts with α-actinin and components of the endosome recycling pathway[J].PLoS One,2012,7(5):e37925. DOI:10.1371/journal.pone.0037925.
[11] Shenje LT, Andersen P, Halushka MK,et al. Mutations in Alström protein impair terminal differentiation of cardiomyocytes[J].Nat Commun,2014,5:3416. DOI:10.1038/ncomms4416.
[12] Louw JJ, Corveleyn A, Jia Y,et al. Homozygous loss-of-function mutation in ALMS1 causes the lethal disorder mitogenic cardiomyopathy in two siblings[J].Eur J Med Genet,2014,57(9):532-535. DOI:10.1016/j.ejmg.2014.06.004.
[13] Favaretto F, Milan G, Collin GB,et al. GLUT4 defects in adipose tissue are early signs of metabolic alterations in Alms1GT/GT, a mouse model for obesity and insulin resistance[J].PLoS One,2014,9(10):e109540. DOI:10.1371/journal.pone.0109540.
[14] Leitch CC, Lodh S, Prieto-Echagüe V,et al. Basal body proteins regulate Notch signaling through endosomal trafficking[J].J Cell Sci,2014,127(Pt 11):2407-2419. DOI:10.1242/jcs.130344.
[15] Mahamid J, Lorber A, Horovitz Y,et al. Extreme clinical variability of dilated cardiomyopathy in two siblings with Alström syndrome[J].Pediatr Cardiol,2013,34(2):455-458. DOI:10.1007/s00246-012-0296-6.
[16] Russell-Eggitt IM, Clayton PT, Coffey R,et al. Alström syndrome. Report of 22 cases and literature review[J].Ophthalmology,1998,105(7):1274-1280.DOI:10.1016/S0161-6420(98)97033-6.
[17] Álvarez-Satta M, Castro-Sánchez S, Valverde D. Alström syndrome: current perspectives[J].Appl Clin Genet,2015,8:171-179.DOI:10.2147/TACG.S56612.
[18] Paisey RB, Paisey RM, Thomson MP,et al. Protection from clinical peripheral sensory neuropathy in Alström syndrome in contrast to early-onset type 2 diabetes[J].Diabetes Care,2009,32(3):462-464. DOI:10.2337/dc08-1584.
[19] Hoffman JD, Jacobson Z, Young TL,et al. Familial variable expression of dilated cardiomyopathy in Alström syndrome: a report of four sibs[J].Am J Med Genet A,2005,135(1):96-98.DOI:10.1002/ajmg.a.30688.
[20] Makaryus AN, Zubrow ME, Marshall JD,et al. Cardiac manifestations of Alström syndrome: echocardiographic findings[J].J Am Soc Echocardiogr,2007, 20(12):1359-1363.DOI:10.1016/j.echo.2007.04.033.
[21] Smith JC, McDonnell B, Retallick C,et al. Is arterial stiffening in Alström syndrome linked to the development of cardiomyopathy?[J].Eur J Clin Invest,2007,37(2):99-105.DOI:10.1111/j.1365-2362.2007.01759.x.
[22] Romano S, Maffei P, Bettini V,et al. Alström syndrome is associated with short stature and reduced GH reserve[J].Clin Endocrinol(Oxf),2013,79(4):529-536. DOI:10.1111/cen.12180.
[23] Joy T, Cao H, Black G, et al. Alström syndrome(OMIM 203800): a case report and literature review[J].Orphanet J Rare Dis,2007,2:49.DOI:10.1186/1750-1172-2-49.
[24] Farmer A, Aymé S, de Heredia ML, et al. EURO-WABB: an EU rare diseases registry for Wolfram syndrome, Alström syndrome and Bardet-Biedl syndrome[J].BMC Pediatr,2013,13:130. DOI:10.1186/1471-2431-13-130.
[25] Kute VB, Vanikar AV, Gumber MR,et al. Bardet-biedl syndrome: a rare cause of chronic kidney disease[J].Indian J Clin Biochem,2013,28(2):201-205. DOI:10.1007/s12291-012-0275-y.
[26] Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease[J].Curr Opin Nephrol Hypertens,2009,18(2):99-106. DOI:10.1097/MNH.0b013e3283262ab0.
[27] Chang MY, Ong AC. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects[J].Nephron Clin Pract,2012,120(1):c25-c34; discussion c35. DOI:10.1159/000334166.
[28] Mockel A, Obringer C, Hakvoort TB,et al. Pharmacological modulation of the retinal unfolded protein response in Bardet-Biedl syndrome reduces apoptosis and preserves light detection ability[J].J Biol Chem,2012,287(44):37483-37494. DOI:10.1074/jbc.M112.386821.

备注/Memo

备注/Memo:
基金项目:贵州省科技计划项目(2012039)
通信作者:李红,Email:lihong3@medmail.com.cn
更新日期/Last Update: 2017-09-30